Gap in the Shire

19 Aug 2005 By Robert Cyran

The UK pharma group wants rival Barr to delay introducing a generic copy of the hyperactivity drug that provides nearly half its revenues. Buying off its rival will not come cheap. But this is a necessary step to keep the cash flowing until sales of new drugs kick in.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)